Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Recommendations

Info

180 Applying Pharmacogenomics in Therapeutics95. Gilotrif [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc;2014.96. Tarceva [package insert]. South San Francisco, CA: Genentech, Inc; 2015.97. Rosell R, Cancereny E, Gervais R, et al. Erlotinib versus standard chemotherapy asfirst-line treatment for European patients with advanced EGFR mutation-positive nonsmall-celllung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2012;13(3):239.98. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-smallcelllung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17(3):889.99. Xalkori [package insert]. New York, NY: Pfizer; 2013.100. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advancedALK-positive lung cancer. N Engl J Med. 2013;368(25):2385.101. Zykadia [package insert]. East Hanover, NJ: Novartis Pharmaceutical; 2014.102. K378 Versus Chemotherapy in Previously Untreated Patients With ALK RearrangedNon-small Cell Lung Cancer. https://clinicaltrials.gov/ct2/show/NCT01828099?term=NCT01828099&rank=1 (accessed April 27, 2015).103. LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients PreviouslyTreated With Chemotherapy (Platinum Doublet) and Crizotinib. https://clinicaltrials.gov/ct2/show/NCT01828112?term=NCT01828112&rank=1 (accessed April 27, 2015).104. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALKrearrangedadvanced non-small-cell lung cancer (AF-001JP study): A single-arm,open-label, phase 1-2 study. Lancet Oncol. 2013;14(7):590.105. De Braekeleer E, Douet-Guilbert N, Rowe D, et al. ABL1 fusion genes in hematologicalmalignancies: A review. Eur J Haemotol. 2011;86(5):361–71.106. Terasawa T, Dahabreh I, Trikalinos T. BCR-ABL mutation testing to predict responseto tyrosine kinase inhibitors in patients with chronic myeloid leukemia. PLoS CurrEvid Genomic Tests. 2011;2:RRN1204. doi: 10.1371/currents.RRN1204.107. Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I:From the second to third generation. Expert Rev Anticancer Ther. 2008;8(9):1387–98.108. Bosulif [package insert]. New York, NY: Pfizer Labs; 2014.109. Iclusig [package insert]. Cambridge, MA: Ariad Pharmaceuticals; 2015.110. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib inmelanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507.111. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma:A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358.112. Mekinist [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014.113. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition inBRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.114. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody inpatients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.115. Keytruda [package insert]. Whitehouse Station, NJ: Merck & Co. Inc; 2015.116. Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015.117. Robert C, Ribas A, Wolchok JD. Anti-programmed-death-receptor-1 treatment withpembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dosecomparisoncohort of a phase 1 trial. Lancet. 2014;384:1109–17.118. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma withoutBRAF mutation. N Engl J Med. 2015;372:320–30.119. Ekhart C, Rodenhuis S, Smits PHM, et al. Relations between polymorphisms in drugmetabolisingenzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa,and carboplatin. Pharmacogenet Genomics. 2008;18(11):1009–15.
7Clinical Applicationsof Pharmacogenomicsin Drug Therapy ofCardiovascular DiseasesTibebe WoldemariamCONTENTSKey Concepts.......................................................................................................... 182Introduction............................................................................................................. 182Warfarin.................................................................................................................. 183Clinical Application........................................................................................... 185Clopidogrel............................................................................................................. 186Clinical Application........................................................................................... 187Aspirin.................................................................................................................... 187Statins...................................................................................................................... 188Clinical Application........................................................................................... 189β-Blockers............................................................................................................... 189Clinical Application........................................................................................... 189Angiotensin-Converting Enzyme Inhibitors........................................................... 190Clinical Application........................................................................................... 190Angiotensin II Receptor Blockers........................................................................... 191Clinical Application........................................................................................... 191Thiazide Diuretics................................................................................................... 191Calcium Channel Blockers..................................................................................... 191Antiarrhythmics...................................................................................................... 192Clinical Application........................................................................................... 193N-Acetyltransferase................................................................................................ 193Conclusion and Future Perspectives....................................................................... 193Study Question........................................................................................................ 194Acknowledgment.................................................................................................... 195References............................................................................................................... 195181
Page 1:
ApplyingPharmacogenomicsin Therapeu
Page 5 and 6:
ApplyingPharmacogenomicsin Therapeu
Page 7:
DedicationWe dedicate this book to
Page 10 and 11:
viiiContentsChapter 10 Pharmacogeno
Page 13 and 14:
EditorsXiaodong Feng, PhD, PharmD,
Page 15 and 16:
ContributorsWeiguo Chen, PhDDepartm
Page 17 and 18:
1Concepts inPharmacogenomics andPer
Page 19 and 20:
Concepts in Pharmacogenomics and Pe
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
2Principles ofPharmacogeneticBiotec
Page 51 and 52:
Principles of Pharmacogenetic Biote
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65:
Page 68 and 69:
52 Applying Pharmacogenomics in The
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
4 ApplyingPharmacogenomicsin Drug D
Page 93 and 94:
Applying Pharmacogenomics in Drug D
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
5 Pharmacogenomicsand Laboratory Me
Page 113 and 114:
Pharmacogenomics and Laboratory Med
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146: Pharmacogenomics and Laboratory Med
Page 157: Pharmacogenomics and Laboratory Med
Page 160 and 161: 144 Applying Pharmacogenomics in Th
Page 217 and 218: 8Clinical Applicationsof Pharmacoge
Page 219 and 220: Pharmacogenomics of CNS Disorder Tr
Page 237 and 238: 9 ApplyingPharmacogenomicsin the Th
Page 239 and 240: Applying Pharmacogenomics in the Th
Page 247 and 248:
Applying Pharmacogenomics in the Th
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
10Pharmacogenomics andAlternative M
Page 261 and 262:
Pharmacogenomics and Alternative Me
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
11 PharmacoeconogenomicsA Good Marr
Page 289 and 290:
Pharmacoeconomics of Pharmacogenomi
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
5’3’5’3’ 5’3’ 5’3’3
Page 305 and 306:
1 2 3 4 5Vysis LSI BCR/ABL + 9q34 t
Page 307:
BIOMEDICAL SCIENCEApplying Pharmaco
show all

Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?